Clinical trial
Effectiveness of Adding Interleukin-2 to Anti-HIV Drugs in Patients Recently…
NCT00006441 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00006441 |
|---|---|
| Title | Effectiveness of Adding Interleukin-2 to Anti-HIV Drugs in Patients Recently Infected With HIV |
| Official title | A Single Center, Randomized Open Label Study of Initial Interleukin-2 Compared to Delayed Interleukin-2 When Added to Zidovudine, 3TC and Nelfinavir In Order to Modulate Immune Function and to Sustain Suppression of HIV-1 Replication Among Those Persons With Primary or Early HIV Infection |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Collaborators | Chiron Corporation Industry Agouron Pharmaceuticals Glaxo Wellcome |
| Status | Completed |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Lamivudine/Zidovudine, Nelfinavir mesylate, Aldesleukin |
| Enrollment | 398 |
| Start date | Feb 1, 2003 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Aug 31, 2001 |
| Last update posted | Mar 9, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: